Small cell lung cancer may respond to combination of immunotherapy and targeted therapy

Researchers at MD Anderson Cancer Center have discovered that a combination of immune checkpoint blockade and targeted therapies that block normal DNA damage repair, such as PARP inhibitors, achieved dramatic tumor reduction in mouse models of small cell lung cancer. The findings, published in Cancer Discovery, suggest a promising new approach for treating patients with this aggressive form of lung cancer.

Lauren Averett Byers, M.D., corresponding author on the study and assistant professor in Thoracic/Head and Neck Medical Oncology at MD Anderson, discusses the study's findings.

For more information, visit https://www.mdanderson.org/new....sroom/small-cell-lun

Request an appointment at MD Anderson by calling 1-877-632-6789 or by completing an online self-referral form: https://my.mdanderson.org/Requ....estAppointment?cmpid